It improbable that the EU will renew its vaccine contract with British-Swedish Astrazeneca, and no negotiations have been entered into with US giant Johnson & Johnson either, says Secretary of State for Economy and Finance Agnes Pannier-Runacher, according to news agency AFP.
"We have not started negotiations with Johnson & Johnson, neither with Astrazeneca, but we're in discussion with Pfizer/Biontech and Moderna," she says.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.